astra deal makes the ipo failure insignificant

Call me mad for saying this without knowing the detail of the Astra deal.....Really if you look at the Astrazeneca announcement where VAST was not valued at all in the SP prior to that announcement it makes the IPO failure late last year seem quite small IMO.

The IPO was offered at the wrong time and we all knew it. Yes ACL lost some money from the IPO (was it something like $3m ?) but this new CEO is cementing income/funding now from a second source and it wont be long before we have a small amount from the European Fonda sales.

We still have a possible IPO of Audeo or some JV so a price of 40 cents IMO is still very low. He is building value in this company and we have cash for phase III completion which may just mean an additional income if the right results come in. As far as the results are concerned we do know they had to extend the study and from memory it was because the patients extended survival rate was better than expected (correct me if I am wrong) so we have to believe that the trial is going well.

I think the SP will struggle to keep 40 over the coming weeks but once we get another Fonda announcement under our belt that confirms DR share is hopefully rising or at least stabilising, add a European announcement and we will have it into the 50s.

Our current CEO is building value based on our expertise. That means income flows are in place and more to follow. If I was an analyst I would be casting my eye over this company over the next 12 months.